Hims & Hers Health - Class A opened lower at $19.56, compared with its previous close of $20.81. In the last trading session, the stock traded between $19.47 and $20.46. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Hims & Hers Health - Class A is now worth
$ 256.21
Giving a profit of
$ 156.21 (156.21%)
Note: Past profits do not guarantee future returns.
Rating from 12 Analysts
Today's Change
$-1.08 (-5.20%)
Day High
$20.46
Day Low
$19.47
Day Open
$19.56
Prev Close
$20.81
Volume
1,07,67,570
1W Return
-25.94%
1M Return
-35.66%
3M Return
-35.38%
6M Return
-32.30%
1Y Return
-50.37%
Market Cap ($ Mn)
4,438
PE Ratio
-
PB Ratio
20.76
PEG Ratio
-
ROE
23.68%
ROCE
9.94%
EPS (TTM)
$-0.14
1 Week
-25.94%
1 Month
-35.66%
3 Months
-35.38%
6 Months
-32.30%
9 Months
18.20%
FTC and seven states expand lawsuit against Hims & Hers over privacy
FTC and seven states filed an amended lawsuit against Hims & Hers for privacy violations. Regulators allege the company shared sensitive health data with Meta and Snap. Complaint cites deceptive subscription models and blocked refund policies. Shares rose 4.99% to $20.08 despite the expanded legal action.
YesterdayHims & Hers Health Inc. Q3FY26 Results: Loss widens to $0.14, revenue up 49%
Reported a Q3 loss of 14 cents per share, missing the 8-cent consensus estimate. Revenue rose 49% YoY to $890.373 million but missed the $892.888 million estimate. Narrowed FY26 revenue guidance to $3.13-$3.15 billion from $3.10-$3.30 billion. Appointed Stanford neuroscientist Andrew Huberman to the board of directors.
YesterdayJefferies lowers Hims & Hers price target to $24, keeps hold
Jefferies lowers Hims & Hers price target from $31 to $24. Analyst Glen Santangelo maintains a Hold rating on the stock. Morgan Stanley and Needham also recently reduced their price targets.
2 days agoHims & Hers Q3FY26 Results: Net loss $33M, revenue misses estimates
Net loss widened to $33 million; EPS missed consensus at $(0.14). Revenue rose 48.65% YoY to $890.373 million, slightly below estimates. Needham cuts price target to $32 from $42, maintaining Buy rating. International revenue quadrupled to $233 million; domestic up 21%. FY26 revenue guidance tightened to $3.13 billion-$3.15 billion.
2 days agoHims & Hers signs deal with Eli Lilly for direct weight loss drug delivery
Hims & Hers and Eli Lilly partner to deliver Zepbound and Foundayo via telehealth. Self-pay pricing starts at $149 per month for Foundayo and $299 for Zepbound. Eli Lilly's Q3 U.S. Zepbound revenue rose 48% to $5.3 billion. Hims & Hers confirms no distribution of compounded GLP-1 drugs.
6 days agoHims & Hers class action lead plaintiff deadline is November 2, 2026
Lead plaintiff deadline for Hims & Hers securities class action is November 2, 2026. Complaint alleges misleading statements on health data privacy and immediate prescription billing. FTC lawsuit on July 29, 2026, triggered a 14.73% stock drop to $25.00 per share. Class period covers purchases between August 4, 2025, and July 29, 2026.
10 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Hims & Hers Health - Class A is now worth
$ 256.21
Giving a profit of
$ 156.21 (156.21%)
Note: Past profits do not guarantee future returns.
